BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yin XF, Zhang Q, Chen ZY, Wang HF, Li X, Wang HX, Li HX, Kang CM, Chu S, Li KF, Li Y, Qiu YR. NLRP3 in human glioma is correlated with increased WHO grade, and regulates cellular proliferation, apoptosis and metastasis via epithelial-mesenchymal transition and the PTEN/AKT signaling pathway. Int J Oncol 2018;53:973-86. [PMID: 30015880 DOI: 10.3892/ijo.2018.4480] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Saponaro C, Scarpi E, Sonnessa M, Cioffi A, Buccino F, Giotta F, Pastena MI, Zito FA, Mangia A. Prognostic Value of NLRP3 Inflammasome and TLR4 Expression in Breast Cancer Patients. Front Oncol 2021;11:705331. [PMID: 34540671 DOI: 10.3389/fonc.2021.705331] [Reference Citation Analysis]
2 dos Santos DC, Rafique J, Saba S, Grinevicius VMAS, Filho DW, Zamoner A, Braga AL, Pedrosa RC, Ourique F, Rai SN. IP-Se-06, a Selenylated Imidazo[1,2-a]pyridine, Modulates Intracellular Redox State and Causes Akt/mTOR/HIF-1α and MAPK Signaling Inhibition, Promoting Antiproliferative Effect and Apoptosis in Glioblastoma Cells. Oxidative Medicine and Cellular Longevity 2022;2022:1-18. [DOI: 10.1155/2022/3710449] [Reference Citation Analysis]
3 Wang M, Jiang S, Zhang Y, Li P, Wang K. The Multifaceted Roles of Pyroptotic Cell Death Pathways in Cancer. Cancers (Basel) 2019;11:E1313. [PMID: 31492049 DOI: 10.3390/cancers11091313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Velloso FJ, Trombetta-Lima M, Anschau V, Sogayar MC, Correa RG. NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer. Biosci Rep 2019;39:BSR20181709. [PMID: 30837326 DOI: 10.1042/BSR20181709] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 11.7] [Reference Citation Analysis]
5 Wu H, Liu J, Zhang Y, Li Q, Wang Q, Gu Z. miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway. Clin Transl Oncol 2021;23:257-64. [PMID: 32524269 DOI: 10.1007/s12094-020-02413-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Li L, Li P, Zhang W, Zhou H, Guo E, Hu G, Zhang L. FERMT1 contributes to the migration and invasion of nasopharyngeal carcinoma through epithelial-mesenchymal transition and cell cycle arrest. Cancer Cell Int 2022;22:70. [PMID: 35144617 DOI: 10.1186/s12935-022-02494-1] [Reference Citation Analysis]
7 Tezcan G, Garanina EE, Alsaadi M, Gilazieva ZE, Martinova EV, Markelova MI, Arkhipova SS, Hamza S, McIntyre A, Rizvanov AA, Khaiboullina SF. Therapeutic Potential of Pharmacological Targeting NLRP3 Inflammasome Complex in Cancer. Front Immunol 2020;11:607881. [PMID: 33613529 DOI: 10.3389/fimmu.2020.607881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Huang Z, Chen H, Wang S, Wei H, Wang X, Shen R, Wang Y, Lin R, Lin J. NLRP3 Overexpression Associated With Poor Prognosis and Presented as an Effective Therapeutic Target in Osteosarcoma. Front Pharmacol 2021;12:724923. [PMID: 34393801 DOI: 10.3389/fphar.2021.724923] [Reference Citation Analysis]
9 Lim J, Kim MJ, Park Y, Ahn JW, Hwang SJ, Moon JS, Cho KG, Kwack K. Upregulation of the NLRC4 inflammasome contributes to poor prognosis in glioma patients. Sci Rep 2019;9:7895. [PMID: 31133717 DOI: 10.1038/s41598-019-44261-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
10 Lin TY, Tsai MC, Tu W, Yeh HC, Wang SC, Huang SP, Li CY. Role of the NLRP3 Inflammasome: Insights Into Cancer Hallmarks. Front Immunol 2020;11:610492. [PMID: 33613533 DOI: 10.3389/fimmu.2020.610492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Otazu GK, Dayyani M, Badie B. Role of RAGE and Its Ligands on Inflammatory Responses to Brain Tumors. Front Cell Neurosci 2021;15:770472. [PMID: 34975408 DOI: 10.3389/fncel.2021.770472] [Reference Citation Analysis]
12 Li LL, Wei L, Zhang N, Wei WY, Hu C, Deng W, Tang QZ. Levosimendan Protects against Doxorubicin-Induced Cardiotoxicity by Regulating the PTEN/Akt Pathway. Biomed Res Int 2020;2020:8593617. [PMID: 32596387 DOI: 10.1155/2020/8593617] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Missiroli S, Perrone M, Boncompagni C, Borghi C, Campagnaro A, Marchetti F, Anania G, Greco P, Fiorica F, Pinton P, Giorgi C. Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer. Cancers (Basel) 2021;13:2297. [PMID: 34064909 DOI: 10.3390/cancers13102297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Chen J, Luo B, Wen S, Pi R. Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug. Invest New Drugs 2020;38:755-64. [PMID: 31414267 DOI: 10.1007/s10637-019-00821-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
15 Lee CH. Reversal of Epithelial-Mesenchymal Transition by Natural Anti-Inflammatory and Pro-Resolving Lipids. Cancers (Basel) 2019;11:E1841. [PMID: 31766574 DOI: 10.3390/cancers11121841] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Su CC, Wang SC, Chen IC, Chiu FY, Liu PL, Huang CH, Huang KH, Fang SH, Cheng WC, Huang SP, Yeh HC, Liu CC, Lee PY, Huang MY, Li CY. Zerumbone Suppresses the LPS-Induced Inflammatory Response and Represses Activation of the NLRP3 Inflammasome in Macrophages. Front Pharmacol 2021;12:652860. [PMID: 34045963 DOI: 10.3389/fphar.2021.652860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]